QuidelOrtho reported third-quarter 2026 revenue of $618.9 million , down 11.6% year over year and below Wall Street consensus estimates. Adjusted earnings per share (EPS) of $0.31 came in ahead of analyst expectations, which ranged from roughly $0.18 to $0.20.
Alamar Biosciences reported third quarter 2026 revenue of $33.5 million , up 68% year over year and above the consensus estimate of about $30.1 million. Net loss narrowed to $0.19 per share , beating the consensus expectation of a $0.22 loss per share.
Comparable sales rose 3% to €4.39 billion, led by Personal Health (+8%) and Connected Care (+5%), while Diagnosis & Treatment was flat. Adjusted EBITA (earnings before interest, taxes, and amortization) climbed to €569 million, lifting the adjusted EBITA margin 70 basis points to 13.0%.
The central target of $18 is a technical milestone — a return to the stock's 52-week high — not an analyst consensus, because NSYS has no credible published analyst price targets. At a recent price of about $11.05 , reaching $18 would require a gain of roughly 63% , a very large move for a thinly traded micro-cap.
Nortech Systems is a micro-cap provider of engineering and manufacturing solutions for complex electromedical devices, electromechanical systems, assemblies, and components. The stock has traded in a relatively narrow range over the trailing 30 days, posting a modest single-digit move of roughly 7%.
The central stock price target of $3.30 is the arithmetic mean of three verified analyst price targets, rounded from an underlying average of roughly $3.33. With the stock recently near $0.54, reaching $3.30 would require a gain of roughly 511% — a very large move even for a high-risk, development-stage medtech name.
InspireMD (NSPR) is a medical device company developing the CGuard Prime carotid stent system for stroke prevention, built on its proprietary MicroNet mesh technology. Over the trailing 30 days, NSPR has moved only about 1% higher versus its closing price from 30 days earlier, following a period of elevated volatility.
SRTS shares rose roughly 10% over the trailing 30-day period, rebounding from levels near the 52-week low following a sharp single-session gain in early November. The stock remains below its late-August peak near $3.54 after a multi-week decline through September and October.
The $5.00 central target is the arithmetic mean of the three most recent, clearly attributed analyst price targets (about $5.17), rounded to a clean level; the individual targets range from $4.00 to $6.00. Sensus Healthcare, Inc. (SRTS) last traded near $2.75, so reaching $5.00 would require an advance of roughly 80%, a very large move by any standard.
Haemonetics (HAE) has shown strong relative momentum in recent months, supported by a plasma-collection supply agreement expansion with CSL Plasma and a series of regulatory approvals. Sensus Healthcare (SRTS) is a much smaller, earlier-stage medical device company whose shares have been pressured by sharply lower revenue and wider losses in recent quarters.
LUNG (Pulmonx Corporation) and SRTS (Sensus Healthcare) are both small-cap medical device companies, but they operate in different niches: minimally invasive lung treatment versus non-invasive skin cancer therapy. Pulmonx recently returned to year-over-year revenue growth and sharply narrowed its losses, reflecting improved commercial execution and cost discipline.
Baird Medical (BDMD) slid during regular trading hours, falling from a $0.138 prior close to roughly $0.10, a -26.7% decline. The drop reflects continued conversion of a dilutive $4.35M senior 8% original-issue-discount convertible note — convertible at 92% of recent VWAP — flooding the float as Baird Medical, holding only about $0.2M in cash, faces acute liquidity strain.
BVS shares declined roughly 17.6% over the last 30 days, with most of the move triggered by a third-quarter revenue miss and a cut to full-year guidance. Third-quarter revenue rose 3% to $142 million but came in below consensus estimates near $149.5 million, pressured by softer bone graft substitute (BGS) sales.
Bioventus shares fell to $10.84 from a previous close of $13.15, a decline of -17.57%, with the drop beginning in after-hours trading following Monday's close and continuing through premarket into Tuesday's regular session. The decline followed mixed Q3 results — an EPS beat of $0.17 versus $0.16 expected, but revenue of $142.4M missing the $149.5M consensus — along with a cut in full-year 2026 revenue guidance to $590M–$595M from $600M–$610M, below estimates.
Commercialization is the central challenge: Phaos generates very limited revenue relative to its cost base, making execution of its sales pipeline the single most important forward-looking variable. AI-assisted imaging is a structural tailwind: Demand for automated quality control and super-resolution imaging in manufacturing and biomedical research supports a growing addressable market for its products.
The $2.40 objective is not an analyst consensus; it reflects a technical stabilization milestone — the post-split equivalent of the roughly $0.16 level where POAS traded before its October 12, 2026 reverse split. Phaos Technology Holdings has no meaningful sell-side coverage, so the figure is drawn from public discussion and market structure rather than a verified average of analyst price targets.
Phaos Technology Holdings (POAS) declined roughly 47.6% over the last 30 days, falling from about $2.10 to about $1.10 per share. The dominant catalyst was an October 2026 one-for-fifteen reverse stock split intended to regain compliance with NYSE American continued listing standards.
Baird Medical (BDMD) shares fell roughly 81.6% over the trailing 30 days, from about $0.75 to $0.14, extending a broader multi-month downtrend. The decline was driven by dilution risk from a $50 million shelf registration and a priced offering, a Weiss Ratings downgrade to "Sell," and heavy sell-side volume in a thinly traded micro-cap.
BEAT is an early-stage, pre-revenue cardiac monitoring developer, while IRTC is a scaled, revenue-generating digital health platform — a sharp contrast in maturity and risk. IRTC generates roughly $825 million in trailing revenue and is approaching profitability, whereas BEAT remains in early commercialization with ongoing net losses.
Cerus reported third quarter 2026 product revenue of $57.7 million , up 10% year over year, with total revenue of $64.0 million including government contracts. The company posted breakeven earnings per share of $0.00 , beating the consensus estimate for a $0.01 loss.